At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Enzastaurin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dose Finding and Randomized, Multicenter, Placebo-Controlled, Phase 2 Study of Enzastaurin and Sunitinib Versus Placebo and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Enzastaurin, Sunitinib, and 1 other intervention for Metastatic Renal Cell Carcinoma. Completed, enrolled 17 participants across 4 sites in 4 countries.
Detailed Summary
This study will compare the effects of Enzastaurin plus Sunitinib versus Sunitinib alone in metastatic Renal Cell Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesAustria, France, Italy, Poland
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJul 2008
Primary CompletionFeb 2010
Study CompletionSep 2018
TodayJul 2026
First PostedJul 3, 2008
Enrollment StartJun 30, 2008
Primary CompletionFeb 15, 2010
Study CompletionSep 5, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 18.0 years ago
Interventions
Enzastaurindrug
Administered orally
Sunitinibdrug
Administered orally
Placebodrug
Administered orally